Stockreport

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)...

MoonLake Immunotherapeutics - Class A Ordinary Shares  (MLTX) 
PDF Clarified path for HS Phase 3 program with study design, patient population and endpoints agreed One dose of SLK (120mg) to be tested with a similar protocol as in Ph [Read more]